Patents by Inventor Jeppe Sturis

Jeppe Sturis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of selective potassium channel openers
    Publication number: 20030125323
    Abstract: The present invention relates to a use of SUR1/Kir6.2 selective potassium channel openers for the preparation of a pharmaceutical composition for the prevention or the treatment of diabetes, and for the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome (PCOS) as well as a pharmaceutical composition for use in the prevention or the treatment of diabetes, and in the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome.
    Type: Application
    Filed: November 25, 2002
    Publication date: July 3, 2003
    Inventor: Jeppe Sturis
  • Use of selective potassium channel openers
    Publication number: 20030109519
    Abstract: The present invention relates to a use of SUR1/Kir6.2 selective potassium channel openers for the preparation of a pharmaceutical composition for the prevention or the treatment of diabetes in women with prior Gestational Diabetes Mellitus (GDM) as well as a pharmaceutical composition for use in the treatment of diabetes in women with prior GDM.
    Type: Application
    Filed: November 25, 2002
    Publication date: June 12, 2003
    Inventor: Jeppe Sturis
  • Combined use of derivatives of GLP-1 analogs and PPAR ligands
    Publication number: 20030022816
    Abstract: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obesity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analogue and a non-thiazolidinedione PPAR ligand.
    Type: Application
    Filed: September 7, 2001
    Publication date: January 30, 2003
    Inventors: Liselotte Bjerre Knudsen, Karsten Wassermann, Jeppe Sturis, Christian Lehn Brand
  • Combined use of derivatives of GLP-1 analogs and PPAR ligands
    Publication number: 20020187926
    Abstract: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obeity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analogue and a non-thiazolidinedione PPAR ligand.
    Type: Application
    Filed: September 13, 2001
    Publication date: December 12, 2002
    Inventors: Liselotte Bjerre Knudsen, Karsten Wassermann, Jeppe Sturis, Christian Lehn Brand